A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Ozempic, Novo Nordisk’s semaglutide-based diabetes treatment, is expected to reap over $22 billion in sales. Eli Lilly and Company’s competing ... OrbiMed, Logos Capital, Lilly Asia Ventures ...

LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited (“Verdiva” or “the Company”) today announced ... and regulatory roles at Novo Nordisk. Dr. Eid notes, “We are excited by ...

The London and San Francisco-based company has emerged with a portfolio ... In the new biotech's sights are the current duopoly of Novo Nordisk and Eli Lilly, whose GLP-1 agonist-based therapies ...

The company’s launch is backed by an oversubscribed Series ... Previously, Dr Eid held senior clinical, medical, and regulatory roles at Novo Nordisk. “We are excited by the potential of our ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Novo Nordisk has underperformed the broad market ... along with a $110 price target. "The company is working with regulators on new indications for its GLP-1 treatments and is also focused on ...

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...